• HOME
  • Endowed Chair Professor
  • Groups
  • Nucleic acid medicine group
  • Cardiovascular disease research group
  • Vascular medicine and epigenetics group
  • Cerebrovascular disease research group
  • Specially appointed researchers group
  • Photographs
  • Recruitment
  • Contact Us
  • Topics
Home > Groups > Publications (Cardiovascular disease research)

Groups

Cardiovascular disease research group
  Leader Members Publications

Publications

Original Articles & Reviews

  1. Muratsu J, Sanada F, Koibuchi N, Shibata K, Katsuragi N, Ikebe S, Tsunetoshi Y, Rakugi H, Morishita R and Taniyama Y; Blocking Periostin Prevented Development of Inflammation in Rhabdomyolysis-Induced Acute Kidney Injury Mice Model. Cells 2022, 11(21), 3388; https://doi.org/10.3390/cells11213388 (registering DOI)
  2. Muratsu J, Kamide K, Fujimoto T, Takeya Y, Sugimoto K, Taniyama Y, Morishima A, Sakaguchi K, Matsuzawa Y and Rakugi H; Lower body mass index potentiates the association between skipping breakfast and prevalence in proteinuria. Frontiers in Front Endocrinol (Lausanne). 2022 Aug 19;13:916374. doi: 10.3389/fendo.2022.916374. eCollection 2022.
  3. Muratsu J , Kamide K, Fujimoto T, Takeya Y, Sugimoto K, Taniyama Y, Morishima A, Sakaguchi K, Matsuzawa Y and Rakugi H; The combination of high levels of adiponectin and insulin resistance are affected by aging in non-obese old peoples. Front Endocrinol (Lausanne) 2022 Jan 7;12:805244. doi: 10.3389/fendo.2021.805244.
  4. Fujikawa T, Sanada F, Taniyama Y, Shibata K, Katsuragi N, Koibuchi N, Akazawa K, Kanemoto Y, Kuroyanagi H, Shimazu K, Rakugi H, Morishita R; Periostin exon-21 antibody neutralization of triple-negative breast cancer cell-derived periostin regulates tumor-associated macrophage polarization and angiogenesis. Cancers (Basel). 2021 Oct 11;13(20):5072. doi: 10.3390/cancers13205072.
  5. Ikeda-Iwabu Y., Taniyama Y., Katsuragi N., Sanada F., Koibuchi N., Shibata K., Shimazu K., Rakugi H., Morishita R; Periostin short fragment including exon 17 via aberrant alternative splicing is required for breast cancer growth and metastasis. Cells 2021 in press
  6. Balbi C., Milano G., Fertig T. E., Lazzarini E., Bolis S., Taniyama Y., Sanada F., Gherghiceanu M., Luscher T.F., Barile L., Vassalli G; An exosomal-carried short periostin isoform induces cardiomyocyte proliferation. Theranostics 2021 in press
  7. Sanada F., Fujikawa T., Shibata K., Taniyama Y., Rakugi H., Morishita R; Therapeutic Angiogenesis Using HGF Plasmid. Annals of Vascular Diseases 2020 Volume 13 Issue 2 Pages 109-115
  8. Otsu R, Taniyama Y, Sanada F, Muratsu J, Shibata K, Fujikawa T, Brule M K, Shimizu H, Rakugi H and Morishita R; Inhibition of Renal Fibrosis and Glomerular Injury by Sacubitril/Valsartan, a Combination Angiotensin Receptor Blocker and Neprilysin Inhibitor, in a Salt-Sensitive Hypertensive Model Using Angiotensin 1 Receptor Knockout Mice: The Contribution of Non-Angiotensin Blocking Effects to Renal Protection. Open Medicine Journal, 2018; 5: 108. Electronic Publication Date: December 28, 2018
  9. Sanada F, Taniyama Y, Muratsu J, Otsu R, Shimizu H, Rakugi H, Morishita R; 1. Gene-therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease. Medicines (Basel). 2018 Mar 30;5(2). pii: E31. doi: 10.3390/medicines5020031
  10. Sanada F, Taniyama Y, Muratsu J, Otsu R, Shimizu H, Rakugi H, Morishita R; Source of Chronic Inflammation in Aging. Front Cardiovasc Med, DOI: 10.3389/fcvm.2018.00012
  11. Nakazawa Y, Taniyama Y, Sanada F, Morishita R, Nakamori S, Morimoto K, Kay T. Yeung K T, and Yang J; Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer. Sci Rep. 2018 Mar 5;8(1):4013. doi: 10.1038/s41598-018-22340-7.
  12. Sanada F, Taniyama Y, Muratsu J, Otsu R, Shimizu H, Rakugi H, Morishita R; IGFBP-5 Induces Cell Senescence. Front Endocrinol (Lausanne). 2018 Feb 20;9:53. doi: 10.3389/fendo.2018.00053. eCollection
  13. Sanada F, Muratsu J, Otsu R, Shimizu H, Koibuchi N, Uchida K, Taniyama Y, Yoshimura S, Rakugi H, and Morishita R; Local Production of Activated Factor X in Atherosclerotic Plaque Induced Vascular Smooth Muscle Cell Senescence. Sci Rep. 2017 Dec 7;7(1):17172. doi: 10.1038/s41598-017-17508-6.
  14. Sanada F, Taniyama Y, Muratsu J, Otsu R, Simizu H, Rakugi H, Morishita R; Source of Chronic Inflammation and Cell Senescence. Front Cardiovasc Med, 2017 in press
  15. Muratsu J., Sanada F., Taniyama Y., Otsu R., Ikeda-Iwabu Y., Brule May K., Shiabata, K. Rakugi H., Morishita R.; HGF Gene Therapy for Therapeutic Angiogenesis in Peripheral Artery Disease. Therapeutic Angiogenesis 2017, p978-981 in press
  16. Muratsu J, Iwabayashi M, Sanada F, Taniyama Y, Otsu R, Rakugi H, Morishita R; Hepatocyte growth factor prevented high-fat diet-induced obesity and improved insulin resistance in mice. Sci Rep. 2017 Mar 9;7(1):130. doi: 10.1038/s41598-017-00199-4.
  17. Nakama T, Yoshida S, Ishikawa K, Kobayashi Y, Abe T, Kiyonari H, Shioi G, Katsuragi N, Ishibashi T, Morishita R, Taniyama Y; Different roles played by Periostin splice variants in retinal neovascularization. Exp Eye Res. 2016 Dec;153:133-140
  18. Sanada F, Taniyama Y, Muratsu J, Otsu R, Iwabayashi M, Carracedo M, Rakugi H, and Morishita R; Activated Factor X Induces Endothelial Cell Senescence Through IGFBP-5. Sci Rep. 2016 Oct 18;6:35580. doi: 10.1038/srep35580
  19. Taniyama Y and Morishita R; Are diuretic addives fit for uncontrolled hypertensive patients receiving telmisartan and amlodine treatment? Hypertension Research 2016 Nov 24.
  20. Zempo H, Suzuki J, Ogawa O, Watanabe R, Fujiu K, Manabe I, Conway SJ, Taniyama Y, Morishita R, Hirata Y, Isobe M, Nagai R; The influence of periostin positive cell-specific Klf5 deletion on aortic thickening in DOCA-salt hypertensive mice. Hypertens Res. 2016. Nov;39(11):764-768
  21. Sanada F, Kanbara Y, Taniyama Y, Otsu R, Carracedo M, Ikeda-Iwabu Y, Muratsu J, Sugimoto K, Yamamoto K, Rakugi H, Morishita R; Induction of angiogenesis by a type III phosphodiesterase inhibitor, cilostazol, through activation of PPAR gamma and cAMP pathways in vascular cells. ATVB, 2016 Mar;36(3):545-52.
  22. Taniyama Y, Katsuragi N, Sanada F, Azuma J, Iekushi K, Koibuchi N, Okayama K, Ikeda-Iwabu Y, Muratsu J, Otsu R, Rakugi H and Morishita R; Selective blockade of periostin exon17 preservre cardiac performance in acute myocardial infarction. Hypertension, 2016 Feb;67(2):356-61.
  23. Chijimatsu R, Kunugiza Y, Taniyama Y, Nakamura N, Tomita T and Yoshikawa H; Expression and pathological effects of periostin in human osteoarthritis cartilage. BMC Musculoskeletal Disorders, 2015 Aug 21;16(1):215.
  24. Sanada F, Taniyama Y, Kanbara Y, Otsu R, Ikeda-Iwabu Y, Carracedo M, Rakugi H, and Morishita R; Gene therapy in peripheral artery disease. Expert Opin Biol Ther. 2015 Jan 29:1-10.
  25. Shimamura M, Nakagami H, Taniyama Y, Morishita R.; Gene therapy for peripheral arterial disease. Expert Opin Biol Ther. 2014 Aug;14(8):1175-1184.
  26. Kusunoki H, Taniyama Y, Otsu Rei, Rakugi H, Morishita R; Anti-inflammatory effects of hepatocyte growth factor (HGF) on vicious cycle of macrophages and adipocytes. Hypertens. Res. 2014 Jun;37(6):500-6.
  27. Sanada F, Taniyama Y, Azuma J, Ikeda-Iwabu Y, Iwabayashi M, Kanbara Y, Rakugi H, Morishita R; Therapeutic angiogenesis by gene therapy for critical limb ischemia - Choice of biological agent -. Immunology, Endoc.& Metab Agents in Med Chem. 2014 Apr;14(1):32-39.
  28. Shimamura M, Taniyama Y, Katsuragi N, Nakagami H, Sato N, Koriyama H, Kurinami H, Wakayama K, Miyake T, Morishita R; Long-term expression of periostin during the chronic stage of ischemic brain injury in mice. Hypertens. Res. 2014 Jun;37(6):494-9.
  29. Sanada F, Taniyama Y, Azuma J, Ikeda-Iwabu Y, Iwabayashi M, Rakugi H, Morishita R; Endothelial Progenitor Cells in Clinical Settings. J Stem Cells. 2014;9(2):117-25
  30. Kusunoki H, Taniyama Y, Rakugi H, Morishita R; Cardiac and renal protective effects of Irbesartan via PPARg/hepatocyte growth factor (HGF) pathway independent of AT1aR blockade in mouse model of salt-sensitive hypertension. J Am Heart Assoc. 2013 Apr 22;2(2):e000103
  31. Shimizu K, Taniyama Y, Azuma J, Sanada F, Iwabayashi M, Yamane Y, Yamasaki H, Akasaki A, and Morishita R; Evaluation of pregabalin therapy in peripheral neuropathy, Immunology, Endoc. & Metab Agents in Med Chem.2013;13:132-138.
  32. Shimizu K, Taniyama Y, Sanada F, Iwabayashi M, Azuma J, Iekushi K, Katsuragi N, Otsu R, Shibata K, Ishikawa Y, Rakugi H, Morishita R; Novel mechanism of hepatocyte growth factor against prevention of inflammation and oxidative stress, Inflammation and Regeneration 2013 Vol. 33, No. 3: 136-142
  33. Chatterjee A, Kusunoki H, Taniyama Y, Rakugi H, and Morishita R; Improvement of metabolic syndrome by irbesartan via the PPARγ/HGF pathway in apolipoprotein E knockout mice; Biomedical Report 2013 1: 65-70
  34. Taniyama Y, Azuma J, Kunugiza Y, Iekushi K, Rakugi H, Morishita R; Therapeutic option of plasmid-DNA based gene transfer; Curr Top in Med Chem 2012 Aug 1;12(15):1630-7.
  35. Shimizu K, Taniyama Y, Sanada F, Iwabayashi M, Azuma J, Iekushi K, Rakugi H, and Morishita R; Hepatocyte growth factor inhibits LPS-induced oxidative stress via epidermal growth factor receptor degradation; Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2687-93.
  36. Shimamura M, Sato N, Nakagami H, Taniyama Y, and Morishita R; Development of nucleic acid drugs for neurological disorders; Curr Top Med Chem. 2012 Aug 1;12(15):1621-9.
  37. Iwabayashi M, Taniyama Y, Sanada F, Azuma J, Iekushi K, Okayama K, Chatterjee A, Rakugi H, Morishita R; Inhibition of Lp(a)-induced functional impairment of endothelial cells and endothelial progenitor cells byhepatocyte growth factor; Biochem Biophys Res Commun. 2012 Jun 22;423(1):79-84
  38. Yokoi T, Azuma J, Nakade Y, Sanada F, Iekushi K, Yoshika M, Masuda M, Komiyama Y, Taniyama Y, Hiroya M, Morishita R, Takahashi H; Comparison between two calcium antagonists: blood pressure reduction and renal effects in hypertensive patients with type 2 diabetes. Immunology, Endoc.& Metab Agents in Med Chem., 2012, in press
  39. Taniyama Y, Azuma J, Iekushi K, Sanada F, Iwabayashi M, Kusunoki H, Okayama K, Otsu R, Rakugi H, Morishita R; The HGF/c-Met receptor system under pathological conditions. Immunology, Endoc.& Metab Agents in Med Chem., 2012, 12, 122-129
  40. Kaga T, Kawano H, Sakaguchi M, Nakazawa T, Taniyama Y and Morishita R; HGF (hepatocyte growth factor) stimulated angiogenesis without inflammation: Differential actions between HGF, VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor). Vascul Pharmacol. 2012 Aug 19;57(1):3-9
  41. Morishita R, Okayama K, Azuma J, Dosaka N, Iekushi K, Sanada F, Kusunoki H, Iwabayashi M, Rakugi H, Taniyama Y; Response to hepatocyte growth factor and cardiomyopathy in dialysis patients; Hypertens. 2012;60:e25-e26
  42. Okayama K, Azuma J, Dosaka N, Iekushi K, Sanada F, Kusunoki H, Iwabayashi M, Rakugi H, Taniyama Y, and Morishita R; Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition; Hypertens. 2012 May;59(5):958-65.
  43. Shimamura M, Taniyama Y, Katsuragi N, Koibuchi N, Kyutoku M, Sato N , Allahtavakoli M, Wakayama K, Nakagami H, and Morishita R; Role of central nervous system periostin in cerebral ischemia, Stroke. 2012 Apr;43(4):1108-14.
  44. Kusunoki H, Taniyama Y, Azuma J, Iekushi K, Sanada F, Iwabayashi M, Otsu R, Okayama K, Rakugi H, Morishita R; Evidence of contribution of perioxisome-proliferator activated receptor gamma; activation to organ protective actions of telmisartan independent of angiotensin II type 1 receptor blockade, Hypertens. 2012 Feb;59(2):308-16.
  45. Iwabayashi M, Taniyama Y, Sanada F, Azuma J, Iekushi K, Kusunoki H, Chatterjee A, Okayama K, Rakugi H and Morishita R; Role of serotoin in angiogenesis: induction of angiogenesis via endothelial 5-HT1B/Akt/eNOS pathway by sarpogrelate in diabetic mice, Atherosclerosis 2012 Feb;220(2):337-42.
  46. Taniyama Y, Azuma J, Rakugi H, Morishita R; Plasmid DNA-based Gene Transfer with Ultrasound and Microbubbles. Current Gene Therapy 2011 Dec 1;11(6):485-90
  47. Iekushi K, Taniyama Y, Kusunoki H, Azuma J, Sanada F, Okayama K, Iwabayashi M, Koibuchi N, Rakugi H, Morishita R; Hepatocyte growth factor attenuates TGF-β- angiotensin II crosstalk through the inhibition of PTEN/Akt pathway, Hypertens. 2011 Aug;58(2):190-6.
  48. Kyutoku M, Taniyama Y, Katsuragi N, Shimizu H, Kunugiza Y, Iekushi K, Koibuchi N, Sanada F, Ohshita Y, Morishita R; Role of periostin in cancer progression and metastasis: Inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int J Mol Med 2011 Aug;28(2):181-6.
  49. Saito Y, Nakagami H, Azuma N, Hirata S, Sanada F, Taniyama Y, Morishita R, Kaneda Y, Sasajima T; Critical Roles of Cold Shock Domain Protein A as an endogenous angiogenesis inhibitor in skeletal muscle;, Antioxidants & Redox Signaling 2011 Oct 15;15(8):2109-20.
  50. Taniyama Y, Takeya Y, Azuma J, Iekushi K, Sanada F, Kusunoki H, Okayama K, Koibuchi N, Rakugi H and Morishita R; HGF as angiogenic factor and therapeutic approach, Current Signal Transduction Therapy 2011, 6, 221-227
  51. Shioyama W, Nakaoka Y, Higuchi K, Minami T, Taniyama Y, Nishida K, Kidoya H, Sonobe T, Hisamichi Naito, Arita Y, Hashimoto T, Kuroda T, Fujio Y, Shirai M, Takakura N, Morishita R, Yamauchi-Takihara K, Kodama T, Hirano T, Mochizuki N, Komuro I; Docking protein Gab1 is an essential component of postnatal angiogenesis after ischemia via HGF/c-Met signaling, Circ Res. 2011 Mar 18;108(6):664-75.
  52. Morishita R, Makino H, Aoki M, Hashiya N, Yamasaki K, Azuma J, Taniyama Y, Sawa Y, Kaneda Y, and Ogihara T; Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor Arterioscler Thromb Vasc Biol. 2010 Mar;31(3):713-20.
  53. Iekushi K, Taniyama Y, Azuma J, Sanada F, Kusunoki H, Yokoi T, Koibuchi N, Okayama K, Rakugi H, and Morishita R; Hepatocyte growth factor attenuates renal fibrosis through TGF-b1 suppression by apoptosis of myofibroblasts, J Hypertens. 2010 Dec;28(12):2454-61.
  54. Nakagami F, Nakagami H, Osako M K, Iwabayashi M, Taniyama Y, Doi T, Shimizu H, Shimamura H, Rakugi H, and Morishita R. Estrogen attenuates vascular remodeling in Lp(a) Transgenic Mice. Atherosclerosis. 2010 Jul;211(1):41-7.
  55. Taniyama Y and Morishita R. “Does therapeutic angiogenesis overcome CKD?” Hypertens Res. 2010 Feb;33(2):114-5.
  56. Suzuki J, Ogawa M, Takayama K, Taniyama Y, Morishita R, Hirata Y, Nagai R and Isobe M. Ultrasound-microbubble mediated ICAM-1 siRNA transfection attenuates neointimal formation after arterial injury in mice. JACC 2010 Mar 2;55(9):904-913.
  57. Sanada F, Taniyama Y, Iekushi K, Azuma J, Koibuchi N, Kusunoki H, Doi T, Aizawa Y, Morishita R Negative action of HGF /c-Met system on angiotensin II signaling via ligand-dependent EGF receptor degradation mechanism in VSMC. Circ. Res 2009 Sep 27(in press)
  58. Sanada F, Taniyama Y, Azuma J, Iekushi K, Dosaka N, Yokoi T, Koibuchi N, Kusunoki H, Aizawa Y, Morishita R. Hepatocyte growth factor, but not vascular endothelial growth factor, attenuated angiotensin II induced EPC senescence; Hypertens. 2009 Jan;53(1):77-82.
  59. Nagao K, Taniyama Y, Kietzmann T, Doi T, Komuro I and Morishita R; HIF-1α signaling upstream of Nkx2.5 is required for development of heart morphology in Xenopus. J Biol Chem. 2008 Apr 25;283(17):11841-9.
  60. Nagao K, Taniyama Y, Koibuchi N, and Morishita R; Constitutive over-expression of VEGF results in reduced expression of Hand-1 during cardiac development in Xenopus. Biochem Biophys Res Commun. 2007 Aug 3;359(3):431-7
  61. Iekushi K, Taniyama Y, Azuma J, Katsuragi N, Dosaka N, Sanada F, Koibuchi N, Nagao K, Ogihara T, and Morishita R; Novel mechanism of valsartan on the treatment of AMI through inhibition of anti-adhesion molecule, periostin. Hypertens. 2007 Jun;49(6):1409-14
  62. Taniyama Y and Morishita R; Development of plasmid DNA-based gene transfer. Journal of the Pharmaceutical Society of Japan 2006, 126(11)1039-1045
  63. Koibuchi N, Taniyama Y, Nagao K, Ogihara T, Kaneda Y, Morishita R; The Effect of VEGF on Blood Vessels and blood cells during Xenopus. Biochemical and Biochem Biophys Res Commun. 2006 May 26; 344(1):339-45
  64. Sato N, Okochi M, Taniyama Y, Takeda M, Ogihara T and Morishita R; Development of new screening system, in vitro Ab sink assay, to identify dissociation of Ab from fibrils Neurobiolo. Dis. 2006 Jun;22(3):487-95
  65. Kunugiza Y, Tomita N, Taniyama Y, Tomita T, Osako M, Tamai K, Tanabe T, Kaneda Y, Yoshikawa H, Morishita M; Acceleration of wound healing by combined gene transfer of hepatocyte growth factor and prostacycline synthase with Shima Jet: Gene Ther. 2006 Aug;13(15):1143-52.
  66. Azuma J, Taniyama Y, Takeya Y, Iekushi K, Aoki M, Dosaka N, Matsumoto K, Nakamura T, Ogihara T and Morishita R; Angiogenic and anti-fibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy: Gene Ther. 2006 Aug;13(16):1206-13
  67. Inagaki H, Suzuki J, Ogawa M, Taniyama Y, Morishita R, and Isobe M Ultrasound-microbubble mediated NF-kb decoy transfection attenuates neointimal formation after arterial injury in mice J Vasc Res. 2005 Oct 20;43(1):12-18
  68. Shimamura M, Sato N, Taniyama Y, Kurinami H, Tanaka H, Takami T, Ogihara T, Tohyama M, Kaneda Y, Morishita R; Gene transfer into adult rat spinal cord using naked plasmid DNA and ultrasound microbubbles: J Gene Med. 2005 Nov;7(11):1468-74.
  69. Taniyama Y, Ito M, Sato K, Kuester C, Veit K, Liao R, Colucci W S, Ivashchenko Y, Walsh K, and Shiojima I. Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy" J Mol Cell Cardiol. 2005;38(2):375-85.
  70. Koike H, Tomita N, Azuma H, Taniyama Y, Yamasaki K, Kunugiza Y, Tachibana K, Ogihara T, Morishita R. An efficient gene transfer method mediated by ultrasound and microbubbles into the kidney. J Gene Med. 2005 Jan;7(1):108-16.
  71. Katsuragi N, Morishita R, Nakamura N, Ochiai T, Taniyama Y, Hasegawa Y, Kawashima K, Kaneda Y, Ogihara T, Sugimura K.; Periostin as a novel factor responsible for ventricular dilation. Circulation. 2004 Sep 28;110(13):1806-13.
  72. Taniyama Y, Shimamura M, Sato N, Tomita N, Endoh M, Azuma J, Iekushi K, Kaneda Y, Ogihara T, Morishita R; Modification of Plasmid DNA-based Gene Transfer with microbubbules. ISTU in press; 2004
  73. Taniyama Y, Shimamura M, Sato N, Tomita N, Endoh R. M, Azuma J, Iekushi K, Kaneda Y, Ogihara T, Morishita R; Modification of Plasmid DNA-based Gene Transfer into Central Nerve System. International Congress Series 2004 1274; 159-163
  74. Yamamoto K, Tomita N, Yoshimura S, Nakagami H, Taniyama Y, Yamasaki K, Ogihara T, Morishita R, Hypoxia-induced renal epithelial cell death through caspase-dependent pathway: Role of Bcl-2, Bcl-xL and Bax in tubular injury. Int J Mol Med. 2004 Oct; 14(4):633-40.
  75. Hashiya N, Aoki M, Tachibana K, Taniyama Y, Yamasaki K, Hiraoka K, Makino H, Yasufumi K, Ogihara T, Morishita R. Local delivery of E2F decoy oligodeoxynucleotides using ultrasound with microbubble agent (Optison) inhibits initial hyperplasia after balloon injury in rat carotid artery model. Biochem Biophys Res Commun. 2004 Apr 30; 317(2):508-14.
  76. Koibuchi N, Kaneda Y, Taniyama Y, Matsumoto K, Nakamura T, Ogihara T, Morishita R. Essential role of HGF (hepatocyte growth factor) in blood formation in Xenopus. Blood. 2004 May 1; 103(9):3320-5.
  77. Shimamura M, Sato N, Taniyama Y, Yamamoto S, Endoh M, Kurinami H, Aoki M, Ogihara T, Kaneda Y, Morishita R.; Development of efficient plasmid DNA transfer into adult rat central nervous system using microbubble-enhanced ultrasound. Gene Ther. 2004 Oct; 11(20):1532-9.
  78. Tomita N, Morishita R, Taniyama Y, Koike H, Aoki M, Shimizu H, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T.; Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003 Mar 18;107(10):1411-7
  79. Taniyama Y and Walsh K, Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth.; J Mol Cell Cardiol. 2002 Oct; 34(10):1241-7.
  80. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Yamasaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Hepatocyte growth factor prevents endothelial cell death through inhibition of bax translocation from cytosol to mitochondrial membrane. Diabetes 2002 Aug;51(8):2604-11
  81. Taniyama Y, Morishita R, Aoki M, Hiraoka K, Yamasaki K, Hashiya N, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T.; Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 2002 Jul;40(1):47-53
  82. Taniyama Y, Tachibana K, Hiraoka K, Aoki M, Yamamoto S, Matsumoto K, Nakamura T, Ogihara T, Kaneda Y, Morishita R. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther 2002 Mar;9(6):372-80
  83. Taniyama Y, Tachibana K, Hiraoka K, Namba T, Yamasaki K, Hashiya N, Aoki M, Ogihara T, Yasufumi K, Morishita Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002 Mar 12;105(10):1233-9
  84. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes Circ 2001 Nov 6;104(19):2344-50
  85. Tomita N, Moriguchi A, Yamasaki K, Taniyama Y, Kotani N, Hashiya N, Yoshida M, Yao M, Higaki J, Ogihara T. A family with von Hippel-Lindau disease revealed by pheochromocytoma. Hypertens Res 2001 Jul;24(4):445-50
  86. Nakagami H, Morishita R, Yamamoto K, Yoshimura SI, Taniyama Y, Aoki M, Matsubara H, Kim S, Kaneda Y, Ogihara T. Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells. Diabetes 2001 Jun;50(6):1472-81
  87. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Shimizu M, Nishii T, Taniyama Y, Asai T, Takiuchi S, Moriguchi K, Ohkuro M, Komai N, Yamada K, Inamoto N, Otsuka A, Higaki J, Ogihara T. Additive effects of nicorandil on coronary blood flow during continuous administration of nitroglycerin. J Am Coll Cardiol 2001 Mar 1;37(3):719-25
  88. Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001 Feb;8(3):181-9
  89. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Matsumoto K, Nakamura T, Kaneda Y, Horiuchi M, Ogihara T. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertens 2001 Feb; 37(2 Part 2):581-6
  90. Taniyama Y, Ito H, Morishita R, Ogihara T. Potential of microvascular reperfusion with adjunctive pharmacological intervention: its impact on myocardial perfusion and functional outcomes in patients with acute myocardial infarction. Drugs 2001;61(4):437-41
  91. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Kim S, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells. J Hypertens 2000 Oct;18(10):1411-20
  92. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei-Kim, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circ. 2000 Jul 11;102(2):246-52
  93. Matsushita H, Morishita R, Nata T, Aoki M, Nakagami H, Taniyama Y, Yamamoto K, Higaki J, Yasufumi K, Ogihara T. Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF-kappaB)-mediated bcl-2 suppression: in vivo evidence of the importance of NF-kappaB in endothelial cell regulation. Circ Res 2000 May 12;86(9):974-81
  94. Matsushita H, Morishita R, Aoki M, Tomita N, Taniyama Y, Nakagami H, Shimozato T, Higaki J, Kaneda Y, Ogihara T Transfection of antisense p53 tumor suppressor gene oligodeoxynucleotides into rat carotid artery results in abnormal growth of vascular smooth muscle cells. Circ. 2000 Mar 28; 101(12):1447-52
  95. Aoki M, Morishita R, Taniyama Y, Kida I, Moriguchi A, Matsumoto K, Nakamura T, Kaneda Y, Higaki J, Ogihara T. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 2000 Mar;7(5):417-27
  96. Higaki J, Aoki M, Morishita R, Kida I, Taniyama Y, Tomita N, Yamamoto K, Moriguchi A, Kaneda Y, Ogihara T. In vivo evidence of the importance of cardiac angiotensin-converting enzyme in the pathogenesis of cardiac hypertrophy. Arterioscler Thromb Vasc Biol 2000 Feb; 20(2):428-34
  97. Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, Aoki M, Yamamoto K, Higaki J, Ogihara T. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertens. 2000 Jan; 35(1 Pt 2):237-43
  98. Aoki M, Morishita R, Taniyama Y, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by Hepatocyte Growth Factor: Potential gene therapy for ischemic diseases. Journal of Atherosclerosis and Thronmosis 2000; 7: 71-76.
  99. Okamura A, Ohishi M, Rakugi H, Katsuya T, Yanagitani Y, Takiuchi S, Taniyama Y, Moriguchi K, Ito H, Higashino Y, Fujii K, Higaki J, Ogihara T. Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty. Angiology 1999 Oct;50(10):811-22
  100. Morishita R, Nakamura S, Hayashi S, Taniyama Y, Moriguchi A, Nagano T, Taiji M, Noguchi H, Takeshita S, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertens. 1999 Jun;33(6):1379-84
  101. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, Hori M, Higashino Y, Fujii K, Minamino T Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999 Mar; 33(3):654-60
  102. Morishita R, Nakagami H, Taniyama Y, Matsushita H, Yamamoto K, Tomita N, Moriguchi A, Matsumoto K, Higaki J, Ogihara T. Oligonucleotide-based gene therapy for cardiovascular disease. Clin Chem Lab Med 1998 Aug;36(8):529-34
  103. Takiuchi S, Ito H, Iwakura K, Taniyama Y, Nishikawa N, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T Ultrasonic tissue characterization predicts myocardial viability in early stage of reperfused acute myocardial infarction. Circ. 1998 Feb 3;97(4):356-62
  104. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, Nishikawa N, Higashino Y, Fujii K, Minamino T Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997 Nov 1; 30(5):1193-9
  105. Iwakura K, Ito H, Takiuchi S, Taniyama Y, Nakatsuchi Y, Negoro S, Higashino Y, Okamura A, Masuyama T, Hori M, Fujii K, Minamino T. Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction. Circ. 1996 Sep 15; 94(6):1269-75.
  106. Ito H, Okamura A, Iwakura K, Masuyama T, Hori M, Takiuchi S, Negoro S, Nakatsuchi Y, Taniyama Y, Higashino Y, Fujii K, Minamino T. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circ. 1996 Jun 1; 93(11):1993-9
  107. Fujii K, Okamura A, Takiuchi S, Taniyama Y, Ohishi M, Ogihara T. Clinical characteristics and therapeutic strategy for acute myocardial infarction in the elderly Nippon Ronen Igakkai Zasshi 1996 Apr; 33(4):249-54

Books

  1. Muratsu J., Sanada F., Taniyama Y., Otsu R., Ikeda-Iwabu Y., Brule May K., Shiabata, K. Rakugi H., Morishita R.
    HGF Gene Therapy for Therapeutic Angiogenesis in Peripheral Artery Disease.
    Therapeutic Angiogenesis 2017, p978-981 in press
  2. Sanada F, Taniyama Y, Azuma J, Ikeda-Iwabu Y, Iwabayashi M, Rakugi H, Morishita R
    Endothelial Progenitor Cells in Clinical Setting.
    Progenitor Cells, Biology, Characterization and Potential Clinical Application, Editor Patrick M. Horton and Brett E. Lawrence, Chapter 5, P87-103
  3. Iwabayashi M, Taniyama Y, Azuma J, Sanada F, Iekushi K, Rakugi H, Morishita R
    Role of Serotonin in Angiogenesis in Diabetes.
    J. L. Mehta, N. S. Dhalla (eds.), Biochemical Basis and Therapeutic Implications of Angiogenesis Advances in Biochemistry in Health and Disease Volume 6, 2013, pp 225-238
  4. Taniyama Y, Shimamura M, Sato N, Tomita N, Endoh R. M, Azuma J, Iekushi K, Kaneda Y, Ogihara T, Morishita R
    Modification of Plasmid DNA-based Gene Transfer into Central Nerve System.
    State of the Art :Ultrasound in Medicine 2004 1274; 159-163
  Leader Members Publications
[Cardiovascular disease research group]
Page Top